Secukinumab in plaque psoriasis—results of two phase 3 trials
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Interleukin-17A is considered to be central to the pathogenesis of psoriasis. We evaluated secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe plaque psoriasis. METHODS: In two phase 3, double-blind, 52-week trials, ERASURE (Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in Psoriasis) and FIXTURE (Full Year Investigative Examination of Secukinumab vs. Etanercept Using Two Dosing Regimens to Determine Efficacy in Psoriasis), we randomly assigned 738 patients (in the ERASURE study) and 1306 patients (in the FIXTURE study) to subcutaneous secukinumab at a dose of 300 mg or 150 mg (administered once weekly for 5 weeks, then every 4 weeks), placebo, or (in the FIXTURE study only) etanercept at a dose of 50 mg (administered twice weekly for 12 weeks, then once weekly). The objective of each study was to show the superiority of secukinumab over placebo at week 12 with respect to the proportion of patients who had a reduction of 75% or more from baseline in the psoriasis area-and-severity index score (PASI 75) and a score of 0 (clear) or 1 (almost clear) on a 5-point modified investigator's global assessment (coprimary end points). RESULTS: The proportion of patients who met the criterion for PASI 75 at week 12 was higher with each secukinumab dose than with placebo or etanercept: in the ERASURE study, the rates were 81.6% with 300 mg of secukinumab, 71.6% with 150 mg of secukinumab, and 4.5% with placebo; in the FIXTURE study, the rates were 77.1% with 300 mg of secukinumab, 67.0% with 150 mg of secukinumab, 44.0% with etanercept, and 4.9% with placebo (P<0.001 for each secukinumab dose vs. comparators). The proportion of patients with a response of 0 or 1 on the modified investigator's global assessment at week 12 was higher with each secukinumab dose than with placebo or etanercept: in the ERASURE study, the rates were 65.3% with 300 mg of secukinumab, 51.2% with 150 mg of secukinumab, and 2.4% with placebo; in the FIXTURE study, the rates were 62.5% with 300 mg of secukinumab, 51.1% with 150 mg of secukinumab, 27.2% with etanercept, and 2.8% with placebo (P<0.001 for each secukinumab dose vs. comparators). The rates of infection were higher with secukinumab than with placebo in both studies and were similar to those with etanercept. CONCLUSIONS: Secukinumab was effective for psoriasis in two randomized trials, validating interleukin-17A as a therapeutic target. (Funded by Novartis Pharmaceuticals; ERASURE and FIXTURE ClinicalTrials.gov numbers, NCT01365455 and NCT01358578, respectively.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“An Ab targeting IL-17 (secukinumab) was approved in 2016 to treat moderate-severe plaque psoriasis [54].”
From The Kallikrein-Kinin System: A Novel Mediator of IL-17-Driven Anti-Candida Immunity in the Kidney (2016) · cites this paper as [54]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
FINLAY, A. Y., & KHAN, G. K. (1994) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1994.tb01167.x · Cited by 5,586
Harrington, L. E., Hatton, R. D., Mangan, P. R., Turner, H., Murphy, T. L., Murphy, K. M., & Weaver, C. T. (2005) · Nature Immunology · doi:10.1038/ni1254 · Cited by 4,742
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17
Park, H., Li, Z., Yang, X. O., Chang, S. H., Nurieva, R., Wang, Y.-H., Wang, Y., Hood, L., Zhu, Z., Tian, Q., et al. (2005) · Nature Immunology · doi:10.1038/ni1261 · Cited by 4,265
Pathogenesis and clinical features of psoriasis
Griffiths, C. E., & Barker, J. N. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61128-3 · Cited by 2,158
Chronic Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17 Immunity
Puel, A., Cypowyj, S., Bustamante, J., Wright, J. F., Liu, L., Lim, H. K., Migaud, M., Israel, L., Chrabieh, M., Audry, M., et al. (2011) · Science · doi:10.1126/science.1200439 · Cited by 1,056
Pivotal Role of Dermal IL-17-Producing γδ T Cells in Skin Inflammation
Cai, Y., Shen, X., Ding, C., Qi, C., Li, K., Li, X., Jala, V. R., Zhang, H.-G., Wang, T., Zheng, J., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.08.001 · Cited by 1,026
Mast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in Psoriasis
Lin, A. M., Rubin, C. J., Khandpur, R., Wang, J. Y., Riblett, M., Yalavarthi, S., Villanueva, E. C., Shah, P., Kaplan, M. J., & Bruce, A. T. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100123 · Cited by 906
Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease
Onishi, R. M., & Gaffen, S. L. (2010) · Immunology · doi:10.1111/j.1365-2567.2009.03240.x · Cited by 894
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
Griffiths, C. E. M., Strober, B. E., van de Kerkhof, P., Ho, V., Fidelus-Gort, R., Yeilding, N., Guzzo, C., Xia, Y., Zhou, B., Li, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0810652 · Cited by 859
Harper, E. G., Guo, C., Rizzo, H., Lillis, J. V., Kurtz, S. E., Skorcheva, I., Purdy, D., Fitch, E., Iordanov, M., & Blauvelt, A. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.65 · Cited by 508
Cited by
Items 901–1,000 of 1,001
Liu, J., Chang, H.-W., Grewal, R., Cummins, D. D., Bui, A., Beck, K. M., Sekhon, S., Yan, D., Huang, Z., Schmidt, T. H., et al. (2021) · JID Innovations · doi:10.1016/j.xjidi.2021.100094 · Cited by 22
“Secukinumab was found to be efficacious in the treatment of psoriasis in two major phase 3 clinical trials, reducing PASI scores, a measure of disease severity, by 75% in over 70% of patients with psoriasis, higher than the response rate achieved by the TNF blocker etanercept (Langley et al., 2014).”
BackgroundMamada, H., Murayama, A., Kamamoto, S., Kaneda, Y., Yoshida, M., Sugiura, S., Yamashita, E., Kusumi, E., Saito, H., Sawano, T., et al. (2022) · Arthritis Care & Research · doi:10.1002/acr.25032 · Cited by 21
“In particular, remarkable progress has been achieved in the treatment of psoriatic arthritis (PsA) over the past 3 decades (15) with the launch of several novel biologic drugs such as risankizumab (16), secukinumab (17), brodalumab (18), and adalimumab (19).”
BackgroundByström, J., Taher, T. E. I., Henson, S. M., Gould, D., & Mageed, R. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.990794 · Cited by 23
“Th17 cells, present in the dermis of patients as IL-17-producing Trm cells, contribute to psoriasis pathology, evidenced by therapeutic efficacy of treatment with anti-IL-17 antibody in reducing plaques (86).”
BackgroundMichalak-Stoma, A., Bartosińska, J., Raczkiewicz, D., Kowal, M., Kozak, J., Gujski, M., Krasowska, D., & Chodorowska, G. (2022) · Medical Science Monitor · doi:10.12659/msm.938277 · Cited by 30
“The crucial role of IL-17A in psoriasis was proven by a good clinical response to the therapies downregulating IL-17A in lesional skin [11-14].”
BackgroundSecukinumab for treating plaque psoriasis
Rothstein, B. E., & Gottlieb, A. B. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1121986 · Cited by 27
“Pivotal trial(s) ERASURE [51] FIXTURE [51] JUNCTURE [52] FEATURE [53] B.”
BackgroundMethodInfluentialSmall molecules and antibodies for the treatment of psoriasis: a patent review (2010–2015)
Chiricozzi, A., Saraceno, R., Novelli, L., Fida, M., Caso, F., Scarpa, R., Costa, L., Perricone, R., Romanelli, M., Chimenti, S., et al. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2016.1192129 · Cited by 23
“group on etanercept.[68] Similarly, another head-to-head study testing secukinumab versus ustekinumab demon-”
BackgroundMethodCurrent status and future prospects for biologic treatments of psoriasis
Cline, A. E., Hill, D., Lewallen, R. S., & Feldman, S. R. (2016) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2016.1202115 · Cited by 28
“Data from phase III trials of each infliximab [23,66], adalimumab [33,67], etanercept [46,48], ustekinumab [63,64,68], secukinumab [69,70], and ixekizumab [71] were compiled and graphed.”
BackgroundMethodBiosimilars for psoriasis: clinical studies to determine similarity
Blauvelt, A., Puig, L., Chimenti, S., Vender, R. B., Rajagopalan, M., Romiti, R., Skov, L., Zachariae, C. O. C., Young, H. S., Prens, E. P., et al. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15067 · Cited by 23
Inflammatory Joint Disorders and Neutrophilic Dermatoses: a Comprehensive Review
Cugno, M., Gualtierotti, R., Meroni, P. L., & Marzano, A. V. (2017) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-017-8629-0 · Cited by 21
Noguchi, M., Nomura, A., Doi, S., Yamaguchi, K., Hirata, K., Shiozaki, M., Maeda, K., Hirashima, S., Kotoku, M., Yamaguchi, T., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-35783-9 · Cited by 23
Harirchian, P., Lee, J., Hilz, S., Sedgewick, A. J., White, B. E. P., Kesling, M., Mully, T. W., Golovato, J., Gray, M., Mauro, T. M., et al. (2018) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.10.046 · Cited by 21
“, infliximab and secukinumab, respectively) now represent some of the most effective psoriasis therapies (Langley et al., 2014; Reich et al., 2005).”
BackgroundCameron, C. G., Druchok, C., Hutton, B., McElligott, S. C., Nair, S., Schubert, A., Situ, A., Varu, A., & Villacorta, R. (2018) · Journal of Psoriasis and Psoriatic Arthritis · doi:10.1177/2475530318818816 · Cited by 27
Ohata, C., Ohyama, B., Katayama, E., & Nakama, T. (2020) · The Journal of Dermatology · doi:10.1111/1346-8138.15247 · Cited by 21
Gordon, K. B., Reich, K., Crowley, J., Korman, N. J., Murphy, F. T., Poulin, Y. P., Spelman, L. J., Yamauchi, P. S., Mendelsohn, A. M., Parno, J. R., et al. (2020) · Journal of Dermatological Treatment · doi:10.1080/09546634.2020.1747590 · Cited by 23
“1 (a variation of 8 PASI points) (13,14), and median baseline PASI scores range from 15–21 (6 PASI points) (29,30).”
BackgroundMrowietz, U., Bachelez, H., Burden, A. D., Rissler, M., Sieder, C., Orsenigo, R., & Jagiello, P. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.06.038 · Cited by 21
Generalized pustular psoriasis—Dawn of a new era in targeted immunotherapy
Neuhauser, R., Eyerich, K., & Boehner, A. (2020) · Experimental Dermatology · doi:10.1111/exd.14171 · Cited by 22
Thaçi, D., Eyerich, K., Pinter, A., Sebastian, M., Unnebrink, K., Rubant, S., Williams, D., & Weisenseel, P. (2022) · British Journal of Dermatology · doi:10.1111/bjd.20481 · Cited by 24
Sevagamoorthy, A., Sockler, P. G., Akoh, C. C., & Takeshita, J. (2022) · Journal of Dermatological Treatment · doi:10.1080/09546634.2022.2114783 · Cited by 22
Potential role of Th17 cells in the pathogenesis of type 2 autoimmune pancreatitis
Loos, M., Lauffer, F., Schlitter, A. M., Kleeff, J. H., Friess, H., Klöppel, G., & Esposito, I. (2015) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-015-1850-4 · Cited by 21
Siegel, S. A. R., & Winthrop, K. L. (2019) · Current Rheumatology Reports · doi:10.1007/s11926-019-0832-y · Cited by 21
Aggarwal, P., & Fleischer, A. B. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13175139 · Cited by 26
Lebwohl, M., Carvalho, A. L., Asahina, A., Zhang, J., Fazeli, M. S., Kasireddy, E., Serafini, P. R., Ferro, T. J., Gogineni, R., & Thaçi, D. (2025) · Dermatology and Therapy · doi:10.1007/s13555-025-01423-0 · Cited by 25
Song, G. G., & Lee, Y. H. (2017) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-017-0355-8 · Cited by 20
The safety of ixekizumab in psoriasis drug therapy
Puig, L. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1709440 · Cited by 22
“1% in the etanercept group [109]; according to Siliq® label [110], 1.”
BackgroundBerstein, G., Zhang, Y., Berger, Z., Kieras, E., Li, G., Samuel, A., Yeoh, T., Dowty, H. V., Beaumont, K. C., Wigger‐Alberti, W., et al. (2020) · Clinical and Experimental Dermatology · doi:10.1111/ced.14412 · Cited by 20
Wierzbowska-Drabik, K. A., Lesiak, A., Skibińska, M., Niedźwiedź, M., Kasprzak, J. D., & Narbutt, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910402 · Cited by 22
“IL-17A inhibitors Secukinumab Ixekizumab Confirmed high, dose-dependent efficacy in improving PSO during short-term 12–16-week treatment [121,122].”
BackgroundLiterature Overview of the IL-17 Inhibition from Psoriasis to COVID-19
Zou, Y., & Meng, Z. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s329252 · Cited by 22
Liu, C.-T., Yen, J.-H. J., Brown, D. A., Song, Y., Chu, M., Hung, Y.-H., Tang, Y.-H., Wu, P., & Yen, H. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114294 · Cited by 24
Jiang, Y., Lu, S., Lai, Y., & Wang, L. (2023) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2023.05.001 · Cited by 21
Lee, C. A., Schreiber, S., Bressler, B. L., Adams, J. W., Oh, D. A., Tang, Y. Q., Zhang, J., Komori, H. K., & Grundy, J. S. (2024) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1379 · Cited by 23
Novel systemic therapies for the treatment of psoriasis
Tan, K. W., & Griffiths, C. E. M. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1109636 · Cited by 26
“In the ERASURE study,[32] 738 patients were randomized to receive either subcutaneous secukinumab 300 mg, 150 mg (administered once weekly for 5 weeks, then every 4 weeks) or placebo, while in the FIXTURE study, 1306 patients received either subcutaneous secukinumab 300 mg, 150 mg, etanercept 50 mg (twice weekly for 1…”
MethodSecukinumab in the Treatment of Generalized Pustular Psoriasis: A Case report
Polesie, S., & Lidholm, A. G. (2016) · Acta Dermato Venereologica · doi:10.2340/00015555-2467 · Cited by 20
Pathogenese der Psoriasis vulgaris
Schäkel, K., Schön, M. P., & Ghoreschi, K. (2016) · Der Hautarzt · doi:10.1007/s00105-016-3800-8 · Cited by 33
Present and future of biologic drugs in primary Sjögren’s syndrome
Sambataro, D., Sambataro, G., Bosco, Y. D., & Polosa, R. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1235698 · Cited by 19
Davison, N., Warren, R. B., Mason, K. J., McElhone, K., Kirby, B., Burden, A. D., Smith, C. H., Payne, K., & Griffiths, C. E. M. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15551 · Cited by 20
“In the UK, the shift towards adalimumab and, more recently, ustekinumab may be a reflection of emerging evidence to suggest that etanercept is less effective.(8,9,11) In contrast, the findings showed that etanercept use remained relatively high in the ROI, potentially due to its long term safety record.”
BackgroundResultMori, H., Arita, K., Yamaguchi, T., Hirai, M., & Kurebayashi, Y. (2016) · Europe PMC (PubMed Central) · doi:10.24546/81009626 · Cited by 20
Mónge-Nájera, J., & Ho, Y. (2017) · Revista de Biología Tropical · doi:10.15517/rbt.v66i1.29875 · Cited by 22
Network Medicine: A Mandatory Next Step for Inflammatory Bowel Disease
de Souza, H. S. P., & Fiocchi, C. (2018) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izx111 · Cited by 21
Georgakopoulos, J. R., Phung, M., Ighani, A., & Yeung, J. (2018) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/1203475418814229 · Cited by 20
Siebert, S., Sweet, K., Dasgupta, B., Campbell, K., McInnes, I. B., & Loza, M. J. (2019) · Arthritis & Rheumatology · doi:10.1002/art.40921 · Cited by 22
Schaap, M. J., van Winden, M. E. C., Seyger, M. M. B., de Jong, E. M. G. J., & Lubeek, S. F. K. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.07.079 · Cited by 22
Understanding and clinical relevance of chronic rhinosinusitis endotypes
Husain, Q. M., & Sedaghat, A. R. (2019) · Clinical Otolaryngology · doi:10.1111/coa.13455 · Cited by 21
Histopathologic findings characteristic of CARD14‐associated papulosquamous eruption
Ring, N. G., Craiglow, B. G., Panse, G., Antaya, R. J., Ashack, K. A., Ashack, R. J., Faith, E. F., Paller, A. S., McNiff, J. M., Choate, K. A., et al. (2019) · Journal of Cutaneous Pathology · doi:10.1111/cup.13633 · Cited by 20
Sugahara, K., Maeda, Y., Shimano, K., Murase, M., Mochiduki, S., Takemoto, K., Kakimoto, T., Utsumi, H., Oshita, K., & Kataoka, H. (2019) · Journal of Immunology Research · doi:10.1155/2019/5821589 · Cited by 20
“In psoriasis, anti-IL-17 antibodies and the anti-IL-23p19 antibody are highly effective [33, 34], but the results of the phase II trial of MT-1303 were inferior to the effects of these antibodies (EudraCT number 2012-005750-27).”
BackgroundFahrbach, K. R., Sarri, G., Phillippo, D., Neupane, B., Martel, S. E., Kiri, S., & Reich, K. (2021) · Dermatology and Therapy · doi:10.1007/s13555-021-00602-z · Cited by 22
Megna, M., Patruno, C., Bongiorno, M. R., Gambardella, A., Guarneri, C., Romita, P., Raimondo, A., Loconsole, F., & Fabbrocini, G. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01163-5 · Cited by 20
Off-Label High-Dose Secukinumab for the Treatment of Moderate-to-Severe Psoriasis
Phung, M., Ighani, A., Georgakopoulos, J. R., Vender, R. B., Giroux, L., Lansang, P., & Yeung, J. (2019) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/1203475419843118 · Cited by 20
Voorhees, A. S. V., Mason, M. A., Harrold, L. R., Guo, N., Guana, A., Tian, H., Herrera, V., & Strober, B. E. (2019) · Journal of Dermatological Treatment · doi:10.1080/09546634.2019.1656797 · Cited by 24
Old and new treatment targets in axial spondyloarthritis
Rodríguez, V. R., & Poddubnyy, D. (2015) · RMD Open · doi:10.1136/rmdopen-2015-000054 · Cited by 20
“tive results without a clinically significant effect in patients with active AS refractory or intolerant to NSAIDs.(42) 43”
BackgroundLiu, L., Davidorf, B., Dong, P., Peng, A., Song, Q., & He, Z. (2024) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2024.07.011 · Cited by 23
“Despite the efficacy of IL-17-blocking drugs like secukinumab and brodalumab in autoimmune diseases such as psoriasis [59 – 61], they have not yielded the expected results in moderate to severe CD, with some patients experiencing severe complications [62,63].”
BackgroundCalabrese, L., Cartocci, A., Rubegni, P., French, L. E., & Kendziora, B. (2025) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.20617 · Cited by 19
Lebwohl, M., Blauvelt, A., Kartman, C. E., Leatherwood, C., Gordon, K. B., Sattar, N. A., Puig, L., Merola, J. F., Siu, K., Wang, R., et al. (2026) · JAMA Dermatology · doi:10.1001/jamadermatol.2026.1753 · Cited by 31
Risankizumab for the treatment of psoriasis
Gu, C., & Yang, J. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1657829 · Cited by 21
Sigurgeirsson, B., Schäkel, K., Hong, C.-H., Effendy, I., Placek, W. J., Rich, P. A., Keefe, D. L., Bruin, G. J. M., Charef, P., Fu, R., et al. (2021) · Journal of Dermatological Treatment · doi:10.1080/09546634.2021.1902925 · Cited by 19
Magnolo, N., Kingo, K., Laquer, V. T., Browning, J., Reich, A., Szepietowski, J. C., Keefe, D. L., Papanastasiou, P., Bao, W., Forrer, P., et al. (2022) · Pediatric Drugs · doi:10.1007/s40272-022-00507-0 · Cited by 22
“Secukinumab was well tolerated at both dosing regimens, and the overall safety profile was consistent with the safety profile established in adult studies [8, 10, 19].”
ResultYang, Y., Chen, Y., Yu, L., Zhang, X., Shang, J., Fan, J., Zhang, R., Ren, J., & Duan, X. (2022) · Inflammation Research · doi:10.1007/s00011-022-01674-z · Cited by 21
Asahina, A., Okubo, Y., Morita, A., Tada, Y., Igarashi, A., Langley, R. G. B., Deherder, D., Matano, M., Vanvoorden, V., Wang, M., et al. (2023) · Dermatology and Therapy · doi:10.1007/s13555-022-00883-y · Cited by 20
“Moreover, the frequency of oral candiasis infections was similar to observations in previous bimekizumab trials [19, 24, 43, 44], and was higher than observations with other IL-17 inhibitors [13, 14].”
ResultSelf-citationPolasek, T. M., Leelasena, I., Betscheider, I., Marolt, M., Kohlhof, H., Vitt, D., Fliegert, F., & Muehler, A. R. (2023) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1243 · Cited by 24
Patrick, M. T., Nair, R. P., He, K., Stuart, P. E., Billi, A. C., Zhou, X., Gudjonsson, J. E., Oksenberg, J. R., Elder, J. T., & Tsoi, L. C. (2023) · Annals of Neurology · doi:10.1002/ana.26672 · Cited by 24
Current and emerging prospects in the psoriatic treatment
Nikam, R. V., Gowtham, M., More, P. S., & Shinde, A. S. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110331 · Cited by 20
Secukinumab in the Treatment of Hidradenitis Suppurativa
Snyder, C. L., Gibson, R. S., Porter, M. L., & Kimball, A. B. (2023) · Immunotherapy · doi:10.2217/imt-2023-0103 · Cited by 19
Schön, M. P. (2014) · Experimental Dermatology · doi:10.1111/exd.12541 · Cited by 19
Wu, D., Hou, S., Zhao, S., Hou, L., Jiao, T., Xu, N., & Zhang, N. (2017) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14125 · Cited by 20
Follistatin‐like protein 1 modulates IL‐17 signaling via IL‐17RC regulation in stromal cells
Campfield, B. T., Eddens, T. J., Henkel, M., Majewski, M., Horne, W. T., Chaly, Y., Gaffen, S. L., Hirsch, R., & Kolls, J. K. (2017) · Immunology and Cell Biology · doi:10.1038/icb.2017.26 · Cited by 27
Current Practice of Therapeutic Drug Monitoring of Biopharmaceuticals in Psoriasis Patients
Hermans, C., Herranz, P., Segaert, S., & Gils, A. (2017) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000401 · Cited by 19
Novel Biologic Agents Targeting Interleukin-23 and Interleukin-17 for Moderate-to-Severe Psoriasis
Chen, Z., Gong, Y., & Shi, Y. (2017) · Clinical Drug Investigation · doi:10.1007/s40261-017-0550-z · Cited by 20
“3% (ERASURE) of patients receiving secukinumab, although the antibodies were non-neutralizing and did not influence the efficacy or increase the rate of AEs [31].”
BackgroundResultInfluentialPariser, D. M., Frankel, E., Schlessinger, J., Poulin, Y. P., Vender, R. B., Langley, R. G. B., Meng, X., Guana, A., & Nyirady, J. (2017) · Dermatology and Therapy · doi:10.1007/s13555-017-0211-4 · Cited by 19
“The efficacy profiles of secukinumab to week 52 in NA and non-NA patients remained similar to previous results from the overall populations [15, 22].”
ResultSelf-citationTengesdal, I. W., Kitzenberg, D., Li, S., Nyuydzefe, M. S., Chen, W., Weiss, J. M., Zhang, J., Waksal, S. D., Zanin‐Zhorov, A., & Dinarello, C. A. (2018) · European Journal of Immunology · doi:10.1002/eji.201847652 · Cited by 19
Kogan, N. N., Raimondo, N., Gusis, S. E., Izcovich, A., Duran, J. A. A., Barahona‐Torres, L., Blanco, O., Quintana, G. B., Briones, M. C., Castro, C., et al. (2019) · International Journal of Dermatology · doi:10.1111/ijd.14471 · Cited by 22
Lee, M., Huang, Y., Lee, J., Lee, S., Kim, T., Aw, D. C., Bao, W., Dee, C. M. A., Guana, A., & Tsai, T. (2019) · The Journal of Dermatology · doi:10.1111/1346-8138.15004 · Cited by 19
A Rare Case of New-Onset Ulcerative Colitis following Initiation of Secukinumab
Achufusi, T. G., Harne, P. S., & Rawlins, S. (2019) · Case Reports in Medicine · doi:10.1155/2019/2975631 · Cited by 21
“08 per 100 patient-years) of new-onset ulcerative colitis [17].”
BackgroundChoi, B. G., Hong, J. Y., Hong, J. R., Hur, M. S., Kim, S. M., Lee, Y. W., Choe, Y. B., & Ahn, K. J. (2019) · Scientific Reports · doi:10.1038/s41598-019-55062-5 · Cited by 24
New Insights Into Novel Therapeutic Targets in ANCA-Associated Vasculitis
Nozaki, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.631055 · Cited by 21
“Th17 Inhibitors Antibodies directed against IL-17 and IL-23 (secukinumab and ustekinumab, respectively) are effectively used in other autoimmune conditions such as psoriasis (92), but no studies of these monoclonal antibodies for the treatment of vasculitis have been conducted despite the existence of a clear rational…”
BackgroundOkura, I., Kamata, M., Asano, Y., Mitsui, A., Shimizu, T., Sato, S., & Tada, Y. (2021) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2021.04.004 · Cited by 22
Blauvelt, A., Shi, N., Somani, N., Burge, R. T., Zhu, B., Ridenour, T., Lew, C. R., Zimmerman, N. M., Atiya, B., & Murage, M. J. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.06.878 · Cited by 19
A review of IL-36: an emerging therapeutic target for inflammatory dermatoses
Hwang, J., Rick, J. W., Hsiao, J. L., & Shi, V. Y. (2022) · Journal of Dermatological Treatment · doi:10.1080/09546634.2022.2067819 · Cited by 22
Usefulness of selected laboratory markers in ulcerative colitis
Mańkowska‐Wierzbicka, D., Swora-Cwynar, E., Poniedziałek, B., Adamski, Z., Dobrowolska, A., & Karczewski, J. (2015) · European Cytokine Network · doi:10.1684/ecn.2015.0363 · Cited by 22
Bhat, R., Leelavathy, B., Aradhya, S., Gopal, M., Pratap, D. V. S., Mubashir, M., Srinivas, P., Pande, S., & Thavkar, A. (2017) · Indian Dermatology Online Journal · doi:10.4103/2229-5178.198765 · Cited by 19
“2%) completed the maintenance period.[8] For the Indian sub‐population, a total of 149 patients were recruited from 13 sites and randomized to 4 treatment groups in the induction period: secukinumab 300 mg (n = 41), secukinumab 150 mg (n = 34), placebo (n = 43), or etanercept (n = 31).”
BackgroundMethodResultInfluentialFernandes, A. R., Martins‐Gomes, C., Santini, A., Silva, A. M., & Souto, E. B. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813667-6.00009-7 · Cited by 26
Lee, Y. H., & Song, G. G. (2017) · Journal of Rheumatic Diseases · doi:10.4078/jrd.2017.24.4.211 · Cited by 19
“Secukinumab is a human, high-affinity, anti-IL-17A monoclonal antibody [7].”
BackgroundBakulev, A. L., Samtsov, A. V., Kubanov, A. A., Khairutdinov, V. R., Kokhan, M. M., Artemeva, A. V., Derbin, S. I., Chernyaeva, E. V., & Ivanov, R. A. (2019) · Vestnik dermatologii i venerologii · doi:10.25208/0042-4609-2019-95-3-54-64 · Cited by 18
Al-Mutairi, N., & Eassa, B. I. (2019) · Advances in Dermatology and Allergology · doi:10.5114/ada.2019.91496 · Cited by 20
Role of innate lymphoid cells in chronic colitis during anti-IL-17A therapy
Park, C. H., Lee, A.-R., Ahn, S. B., Eun, C. S., & Han, D. S. (2020) · Scientific Reports · doi:10.1038/s41598-019-57233-w · Cited by 19
Assessment of serum biomarkers in patients with plaque psoriasis on secukinumab
Morita, A., Tani, Y., Matsumoto, K., Yamaguchi, M., Teshima, R., & Ohtsuki, M. (2020) · The Journal of Dermatology · doi:10.1111/1346-8138.15278 · Cited by 19
Ruíz‐Villaverde, R., Rodriguez‐Fernandez‐Freire, L., Galán‐Gutiérrez, M., Hita, J. C. A., & Martínez-Pilar, L. (2020) · International Journal of Dermatology · doi:10.1111/ijd.14819 · Cited by 22
Darch, K., Holland, T., & Spelman, L. J. (2020) · Case Reports in Medicine · doi:10.1155/2020/9404505 · Cited by 19
“Secukinumab (Cosentyx), a fully-human monoclonal antibody that acts by selectively binding and neutralising the proinflammatory cytokine IL-17A, is widely used for the treatment of both chronic plaque psoriasis and psoriatic arthritis, with FDA approval for the use in moderate-tosevere chronic plaque psoriasis receive…”
BackgroundInfluentialEksin, M. A., Erden, A., Güven, S. C., Armağan, B., Özdemir, B., Karakaş, Ö., Omma, A., & Küçükşahin, O. (2022) · Immunotherapy · doi:10.2217/imt-2021-0128 · Cited by 18
Strychalski, M. L., Brown, H. S., & Bishop, S. (2022) · JAAD International · doi:10.1016/j.jdin.2022.08.008 · Cited by 23
Li, Y., Lu, J., Zhong, X., Yu, Y., Yu, N., Wang, Y., Yi, X., Ding, Y., & Shi, Y. (2022) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s387759 · Cited by 18
Blauvelt, A., Pariser, D. M., Tyring, S. K., Bagel, J., Alexis, A. F., Soung, J., Armstrong, A. W., Muscianisi, E., Kianifard, F., Steadman, J., et al. (2023) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2023.01.003 · Cited by 21
The economic burden and quality of life of patients with psoriasis treated with biologics in China
Min, S., Wang, D., Xia, J., Lin, X., & Jiang, G. (2023) · Journal of Dermatological Treatment · doi:10.1080/09546634.2023.2247106 · Cited by 20
“In this study, investigators did not use etanercept due to its relatively slow onset (16,17) and high injection frequency compared to other biologics.”
BackgroundLebwohl, M., Iversen, L., Eidsmo, L., Krueger, J. G., Suárez‐Fariñas, M., Tomalin, L. E., Kolbinger, F., You, R., & Milutinovic, M. (2023) · Clinical and Experimental Dermatology · doi:10.1093/ced/llad329 · Cited by 18
Physiological roles of human interleukin‐17 family
Liu, Y., Ouyang, Y., You, W., Liu, W., Cheng, Y., Mai, X., & Shen, Z. (2023) · Experimental Dermatology · doi:10.1111/exd.14964 · Cited by 25
Korman, N. J., Sofen, H. L., Fretzin, S., Rich, P. A., Zhao, Y., Herrera, V., Nyirady, J., Williams, N., Mordin, M., & Tyring, S. K. (2016) · Journal of Dermatological Treatment · doi:10.1080/09546634.2016.1255306 · Cited by 23
“have provided a detailed description of the study designs and clinical outcomes (20).”
BackgroundResultInfluentialPuig, L., Notario, J., Jiménez-Morales, A., Moreno-Ramírez, D., López‐Ferrer, A., Gozalbo, I., Prades, M., Lizán, L., & Blanch, C. (2017) · Journal of Dermatological Treatment · doi:10.1080/09546634.2017.1364687 · Cited by 18
“These results are consistent with previously published studies showing that the most efficacious drugs are the most efficient (18,22,43).”
ResultTreatment strategies for psoriatic arthritis
Schemoul, J., Poulain, C., & Claudepierre, P. (2017) · Joint Bone Spine · doi:10.1016/j.jbspin.2017.11.001 · Cited by 18
Yosipovitch, G., Soung, J., Weiss, J., Muscianisi, E., Meng, X., Gilloteau, I., & Elewski, B. (2019) · Acta Dermato Venereologica · doi:10.2340/00015555-3195 · Cited by 18
Lo, Y., & Tsai, T. (2019) · British Journal of Dermatology · doi:10.1111/bjd.18174 · Cited by 18
IL-23/IL-17 INHIBITORS IN IMMUNOINFLAMMATORY RHEUMATIC DISEASES: NEW HORIZONS
Nasonov, E. L., Korotaeva, T. V., Дубинина, Т. В., & Lila, A. M. (2019) · Rheumatology Science and Practice · doi:10.14412/1995-4484-2019-400-406 · Cited by 25
Kawasaki, Y., Kamata, M., Shimizu, T., Nagata, M., Fukaya, S., Hayashi, K., Fukuyasu, A., Tanaka, T. L., Ishikawa, T., Ohnishi, T., et al. (2020) · The Journal of Dermatology · doi:10.1111/1346-8138.15511 · Cited by 20
Metadata
- Authors
- Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., Rivas, E., Tsai, T.-F., Wasel, N., Tyring, S., Salko, T., Hampele, I., Notter, M., Karpov, A., Helou, S., & Papavassilis, C.
- Affiliations
- Dalhousie University (CA)
- University of Alabama at Birmingham (US)
- Mount Sinai Hospital (US)
- Dermatologikum Hamburg (DE)
- Manchester Academic Health Science Centre (GB)
- Probity Medical Research (CA)
- Hospital de Sant Pau (ES)
- Jikei University School of Medicine (JP)
- University of Iceland (IS)
- National Taiwan University (TW)
- Center for Clinical Studies (US)
- Novartis (Switzerland) (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-07-24
- Volume
- 371
- Issue
- 4
- Pages
- 326-338
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1973354423
- Cited by
- 1,997
- References
- 25
- Citations by year
- 2026: 96 · 2025: 107 · 2024: 116 · 2023: 142 · 2022: 146 · 2021: 165 · 2020: 198 · 2019: 230 · 2018: 201 · 2017: 223 · 2016: 203 · 2015: 146 · 2014: 19
- FWCI
- 90.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (acceptedVersion)
- Digital Access to Libraries (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- GRO (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Rheumatology › Spondyloarthritis Studies and Treatments
- Keywords
- secukinumab, plaque psoriasis, IL-17A, anti-IL-17A monoclonal antibody, etanercept, PASI 75, dosing regimen, biologic therapy, treatment efficacy and safety, erasure, fixtures, Psoriasis Area and Severity Index
- MeSH terms
- Etanercept, Adult, Antibodies, Antibodies, Monoclonal, Double-Blind Method, Female, Humans, Immunoglobulin A, Immunoglobulin G, Immunosuppressive Agents, Infections, Injections, Subcutaneous, Male, Middle Aged, Psoriasis, Receptors, Tumor Necrosis Factor, Interleukin-17, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.